On the opening post — agreed on the reasoning, with one qualification. Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here. If anyone can point at the primary source I would be grateful.
Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below.
Collecting what is known about cagrilintide alone in one place, because it is currently spread across a category, two tag pages and a thread that is hard to find.
This is a summary rather than new work, and I have attributed each part to where I found it.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
Adding it because I spent an afternoon working it out and nobody should have to twice.
The opening post is right about the mechanism and I think understates the practical bit.
Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.
The claim is narrower than it sounds, and deliberately so.
On the opening post — agreed on the reasoning, with one qualification.
Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.
If anyone can point at the primary source I would be grateful.
Picking up post #5: that is the part I would want checked first.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
I would rather post the uncertainty than round it away.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
None of the above is medical advice and I am not qualified to give any.
Clear enough that I do not think I have a follow-up, which is unusual.
For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.
If anyone has run this properly I would rather read that than my own guess.
Where the cagrilintide alone reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
On dosing intervals: the long-acting design supports weekly administration, and the escalation schedules in the published trials are gentler than the compound's potency alone would suggest. Tolerability is the constraint.
Two people can read the same figure differently here and both be reasonable.
Worth separating two things that post #12 runs together.
Anyone reading a purity result for cagrilintide should know that its aggregation behaviour makes sample handling matter more than usual. A result on a sample that was warmed and cooled several times in transit is measuring the transit as much as the material.
The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.
Filing this under things that are true until someone shows me otherwise.
Taking post #14 at face value and following it one step further.
Worth distinguishing the combination product from the two components bought separately and mixed. Those are different pharmaceutical objects and nothing published about the first applies to the second.
Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.
The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.
That is the shape of it. The detail is where I would expect to be corrected.
Post #17 describes the usual case. This is about the unusual one.
The most useful reply I ever got about cagrilintide alone was a request to state my units. It sounds like pedantry and it has saved me twice.
Adding the measurement that post #21 says would settle it.
Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.
The general answer and the answer for your case may diverge here.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.
The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination trials were designed to find out rather than something to be assumed.
The arithmetic in post #25 is right; the assumption feeding it is the part to check.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
That matches what I have seen, for whatever a single anecdote is worth.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
The short version is the first sentence; the rest is why.
Combination products complicate the certificate question considerably. Two active components mean two purity determinations and a ratio, and a single figure for a combination tells you almost nothing.
Posted with less confidence than the sentence structure implies.
For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.